Lpathomab / Apollo Endosurgery - LARVOL DELTA

Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding. (PubMed, Lipids Health Dis) - "Antibody binding specificity and sensitivity, particularly involving lipid ligands, can be assessed in solution and without labels using FSA-CIR. These findings could affect interpretations of both current and past basic and clinical studies employing 504B3 and related anti-LPA antibodies."

Journal

Lpath receives first US patent for anti-LPA antibody, Lpathomab (Lpath) - Lpath received official notification from the US Patent & Trademark Office (USPTO) that it has been issued a key patent protecting Lpathomab; The newly issued US Patent No. 8,158,124 claims antibody compositions directed against LPA, a bioactive lipid that has been validated as a target in multiple disease states

Patent update • Fibrosis

Validation of lysophosphatidic acid as a target for patients with traumatic brain injury (Neuroscience 2016) - "This data may identify a TBI patient cohort with higher LPA that would most likely benefit from anti-LPA intervention therapy. Lpath’s Lpathomab has shown excellent safety and tolerability profiles in a Phase 1a safety trial with healthy human volunteers, positioning Lpathomab for clinical trials in a targeted TBI patient population where LPA levels are elevated."

Biosimilar • Demo Pain • Ophthalmology • Pain

Lpathomab offers hope in billion-dollar neurotrauma and pain markets (SeekingAlpha) - "Lpathomab is currently conducting pre-clinical trials and is expected to begin Phase I trials in 2014"

Anticipated new P1 trial • Fibrosis